I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa
SpringerOpen
Published 2018
SpringerOpen
Published 2018
| Publication Date: |
2018-03-06
|
|---|---|
| Publisher: |
SpringerOpen
|
| Electronic ISSN: |
2191-219X
|
| Topics: |
Medicine
|
| Published by: |
| _version_ | 1836398818834251776 |
|---|---|
| autor | Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa |
| beschreibung | I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (... |
| citation_standardnr | 6183901 |
| datenlieferant | ipn_articles |
| feed_id | 149338 |
| feed_publisher | SpringerOpen |
| feed_publisher_url | http://www.springer.com/ |
| insertion_date | 2018-03-06 |
| journaleissn | 2191-219X |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | SpringerOpen |
| quelle | EJNMMI Research |
| relation | https://ejnmmires.springeropen.com/articles/10.1186/s13550-018-0374-8 |
| search_space | articles |
| shingle_author_1 | Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa |
| shingle_author_2 | Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa |
| shingle_author_3 | Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa |
| shingle_author_4 | Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa |
| shingle_catch_all_1 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (... Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa SpringerOpen 2191-219X 2191219X |
| shingle_catch_all_2 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (... Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa SpringerOpen 2191-219X 2191219X |
| shingle_catch_all_3 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (... Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa SpringerOpen 2191-219X 2191219X |
| shingle_catch_all_4 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma I-124 codrituzumab (aka GC33), an antibody directed at Glypican 3, was evaluated in patients with hepatocellular carcinoma (HCC). Fourteen patients with HCC underwent baseline imaging with I-124 codrituzumab (... Jorge A. Carrasquillo, Joseph A. O’Donoghue, Volkan Beylergil, Shutian Ruan, Neeta Pandit-Taskar, Steven M. Larson, Peter M. Smith-Jones, Serge K. Lyashchenko, Norihisa Ohishi, Toshihiko Ohtomo and Ghassan K. Abou-Alfa SpringerOpen 2191-219X 2191219X |
| shingle_title_1 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| shingle_title_2 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| shingle_title_3 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| shingle_title_4 | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| timestamp | 2025-06-30T23:33:07.637Z |
| titel | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| titel_suche | I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma |
| topic | WW-YZ |
| uid | ipn_articles_6183901 |